SuperworthVyome EPS HIND
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.10
- Fiscal year 2024
- −$2573.82
Vyome's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.10.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$2573.82 | n/a |
| FY2023 | −$21892.00 | n/a |
| FY2022 | −$621238.00 | n/a |
| FY2021 | −$1517976.00 | n/a |
| FY2020 | −$1754500.00 | n/a |
| FY2019 | −$69556500.00 | n/a |
| FY2018 | −$1640684628000.00 | n/a |
| FY2017 | −$4560192000000.00 | n/a |
| FY2016 | −$868365792000000.13 | n/a |
| FY2015 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.10 | n/a | n/a | |
| Q1 FY26 | −$0.15 | n/a | n/a | |
| Q3 FY25 | −$3.12 | n/a | −$1811.61 | |
| Q2 FY25 | −$799.90 | n/a | −$3227.59 | |
| Q1 FY25 | −$761.59 | n/a | −$2793.93 | |
| Q4 FY24 | −$247.00 | n/a | −$2573.82 | |
| Q3 FY24 | −$1419.10 | n/a | −$2970.82 | |
| Q2 FY24 | −$366.24 | n/a | −$7487.72 | |
| Q1 FY24 | −$541.48 | n/a | −$13385.48 | |
| Q4 FY23 | −$644.00 | n/a | −$21892.00 | |
| Q3 FY23 | −$5936.00 | n/a | −$217172.00 | |
| Q2 FY23 | −$6264.00 | n/a | −$367894.00 |
Against its peers
Companies in Drug Manufacturers - General nearest Vyome's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| HINDVyome | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Vyome
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.